News
03-25-2015, 05:50 AM
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.
More... (http://www.news-medical.net/news/20150325/CASI-initiates-ENMD-2076-Phase-2-trial-in-Chinese-patients-with-triple-negative-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20150325/CASI-initiates-ENMD-2076-Phase-2-trial-in-Chinese-patients-with-triple-negative-breast-cancer.aspx)